Borosilicate Glass Market

Overview

The global Borosilicate Glass Market was valued at USD 2.7 billion in 2025 and is projected to reach USD 4.3 billion by 2034, growing at a CAGR of 5.3% during the forecast period (2026–2034). The market is driven by rising pharmaceutical packaging demand for chemically inert Type I glass, expanding laboratory and diagnostic testing infrastructure, and growing adoption of borosilicate glazing in solar thermal collectors and precision electronics applications. The market is shifting from conventional, commodity-grade laboratory and cookware glass toward high-precision, application-specific formulations engineered for pharmaceutical containment, semiconductor processing and renewable energy applications. Government initiatives such as the United States Pharmacopeia and European Pharmacopoeia Type I glass standards, which mandate strict chemical durability testing for primary pharmaceutical packaging, continue to reinforce demand for certified borosilicate tubing across the injectable drug industry. Government-backed domestic manufacturing programs, including India’s production-linked incentive framework for pharmaceutical intermediates and packaging, are encouraging local capacity investment in borosilicate glass tubing and vial conversion. North America held the largest share of the market in 2025, supported by extensive pharmaceutical manufacturing infrastructure and high demand for laboratory glassware across the United States. Asia-Pacific is expected to be the fastest-growing region during the forecast period, propelled by expanding pharmaceutical production, solar thermal manufacturing, and electronics assembly capacity across China and India.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Shift Toward Ready-to-Use, Pre-Sterilized Vial Formats Emerging as a Transformational Trend

• Pharmaceutical manufacturers are increasingly specifying washed, depyrogenated and pre-sterilized borosilicate vials that can be integrated directly into aseptic fill-finish lines rather than requiring in-house preparation. This shift is compressing production timelines for injectable drug manufacturers while reducing contamination risk during the filling process.
• Converters are engineering vial geometries and surface treatments specifically to reduce glass-to-glass contact and particulate generation during nested packaging and automated handling. These design changes improve cosmetic quality and mechanical durability, directly reducing rejection rates on high-speed fill-finish lines used for biologics and vaccines.
• Growth in gene therapy, mRNA and other deep-cold-stored biologics is pushing tubing manufacturers to develop vial geometries engineered specifically to withstand the thermal stress of freezing and thawing cycles down to extremely low temperatures. This specialized engineering is expanding the addressable product range for premium borosilicate vial formats beyond standard injectable packaging.
• SCHOTT announced on 12 August 2025 that it had become the first company in India to locally manufacture high-precision syringe and cartridge glass tubing at its Jambusar, Gujarat facility, positioning the site as Asia’s largest producer of syringe and cartridge glass tubing to meet rising GLP-1 injectable demand.

KEY MARKET DRIVER

Rising Global Demand for Injectable Drug Packaging is the Key Driver

• Pharmaceutical manufacturers continue to specify Type I borosilicate glass as the default material for injectable drug containment because it offers the lowest rate of chemical interaction with sensitive drug formulations among commercially available packaging materials. This chemical inertness is non-negotiable for biologics, vaccines and other high-value injectable therapies.
• Expanding global production of biologics, vaccines and GLP-1 receptor agonist therapies is directly increasing the volume of vials, cartridges and syringes required industry-wide. Each new injectable drug approval adds incremental, recurring demand for certified pharmaceutical-grade glass tubing throughout the product’s commercial lifecycle.
• Laboratory and diagnostic testing volumes continue to expand alongside growing healthcare infrastructure investment in emerging markets, sustaining demand for borosilicate beakers, flasks, test tubes and other reusable labware that must withstand repeated sterilization and thermal cycling.
• Stevanato Group reported on 6 November 2025 that revenue from its high-value drug containment solutions, including glass syringes and cartridges for GLP-1 and biologic therapies, increased 47% year-over-year to a record EUR 147.9 million in the third quarter of 2025, reaching 49% of total company revenue.

KEY MARKET OPPORTUNITY

Expansion of Solar Thermal and Sustainable Glass Manufacturing Creates Significant Market Opportunity

• Growing installation of evacuated tube solar thermal collectors for residential and commercial water heating is creating sustained demand for borosilicate glass tubing engineered to withstand large temperature swings and hail impact. This application represents a volume opportunity distinct from the higher-value pharmaceutical packaging segment.
• Post-consumer recycled cullet integration is opening a differentiation opportunity for producers able to certify recycled content without compromising the chemical purity required for pharmaceutical and laboratory applications. Producers that achieve independent certification for recycled-content borosilicate products are positioned to capture demand from customers pursuing sustainability commitments.
• Precision electronics and semiconductor equipment manufacturers are increasingly specifying low-iron, float-process borosilicate sheet glass for display substrates, inspection windows and process equipment, opening a growing specialty application beyond the material’s traditional pharmaceutical and laboratory use cases.
• SGD Pharma showcased its Sealian internal surface treatment platform and Idency premium molded vial range at CPHI Frankfurt in October 2025, demonstrating continued product innovation in barrier-treated and high-durability molded glass packaging for sensitive parenteral drug formulations.

Borosilicate Glass Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Type

Tubing held the largest share of the borosilicate glass market in 2025, reflecting its position as the essential feedstock for pharmaceutical vials, ampoules, syringes and cartridges, which together represent the highest-value application category for the material. Glass tubing manufactured through the Danner or Vello drawing processes is converted by pharmaceutical packaging companies into billions of primary containers annually, and the tight dimensional tolerances required for injectable drug packaging keep tubing the largest and most technically demanding product category by both volume and revenue within the overall borosilicate glass market.

Sheets are projected to grow at the fastest rate during the forecast period, driven by expanding demand for float-process borosilicate glass in solar thermal collector glazing, precision electronics substrates and architectural and industrial inspection windows. Float-process manufacturing allows producers to supply large-format, uniform-thickness sheet glass at lower unit cost than blown or molded formats, and growing installation of solar water heating systems alongside expanding electronics manufacturing capacity is accelerating demand for sheet glass faster than any other product category.

Type categories include

• Tubing (Dominating Segment)
• Sheets (Fastest-growing Segment)
• Rods
• Others (Fiber, Frit, Cullet)

Analysis by Manufacturing Process

The tube drawing process held the largest share of the market in 2025, as it remains the only established commercial method capable of producing the precise wall thickness and diameter tolerances required for pharmaceutical-grade glass tubing. Producers rely on continuous drawing techniques to manufacture tubing that meets United States Pharmacopeia and European Pharmacopoeia dimensional and chemical durability requirements, and the scale of global pharmaceutical packaging demand keeps tube drawing the dominant manufacturing process across the industry.

The float process is projected to grow at the fastest rate during the forecast period, supported by rising demand for large-format, uniform-thickness borosilicate sheet glass used in solar thermal glazing, electronics substrates and inspection windows. Float processing produces flat glass with excellent optical clarity and low surface distortion at a lower per-unit cost than alternative flat glass forming methods, and expanding solar thermal and electronics manufacturing capacity is driving float-process capacity investment faster than tube or rod drawing capacity.

Manufacturing Process categories include

• Tube Drawing Process (Dominating Segment)
• Float Process (Fastest-growing Segment)
• Rod Drawing Process

Analysis by Application

Pharmaceutical packaging held the largest application share of the market in 2025, as vials, ampoules, cartridges and syringes manufactured from Type I borosilicate glass remain the regulatory standard for injectable drug containment worldwide. Rising global production of biologics, vaccines and GLP-1 receptor agonist therapies continues to expand the volume of pharmaceutical-grade tubing converted into primary containers each year, keeping this application the largest single source of borosilicate glass demand by a wide margin.

Solar thermal collectors are projected to grow at the fastest rate during the forecast period, driven by expanding installation of evacuated tube solar water heating systems across residential, commercial and industrial applications, particularly in markets with strong government-backed renewable energy incentives. Borosilicate glass’s combination of high light transmittance, low thermal expansion and resistance to hail impact makes it the preferred material for the outer tube of evacuated solar collectors, positioning this application as the fastest-growing demand category for the material.

Application categories include

• Pharmaceutical Packaging (Dominating Segment)
• Solar Thermal Collectors (Fastest-growing Segment)
• Laboratory Glassware
• Cookware and Kitchenware
• Electronics and Optics

Analysis by End-Use Industry

The pharmaceutical and healthcare industry held the largest share of the market in 2025, reflecting its position as the single largest consumer of certified borosilicate glass tubing for injectable drug packaging, laboratory diagnostics and medical device components. Stringent regulatory requirements for container chemical durability, combined with sustained global growth in biologics and vaccine production, continue to anchor pharmaceutical and healthcare as the largest end-use category for the material by a substantial margin over other industries.

The renewable energy industry is projected to grow at the fastest rate during the forecast period, driven by expanding solar thermal water heating installations across residential and commercial buildings in markets with supportive government renewable energy policies. As countries continue to expand solar thermal infrastructure to reduce reliance on conventional water heating, demand for borosilicate glass tubing used in evacuated tube collectors is expanding faster than demand from any other end-use industry.

End-Use Industry categories include

• Pharmaceutical and Healthcare (Dominating Segment)
• Renewable Energy (Fastest-growing Segment)
• Food and Beverage
• Industrial and Chemical Processing
• Electronics
• Semiconductor

By Region

Borosilicate Glass Market Share 2025, (CAGR)

North America

33%

South America

xx%

Europe

xx%

Middle East Africa

xx%

Asia Pacific

26%

North America held the largest share of the borosilicate glass market in 2025, accounting for an estimated 33 percent of global revenue, supported by extensive pharmaceutical manufacturing infrastructure and strong demand for laboratory glassware across research institutions and diagnostic laboratories in the United States. The United States is the region’s largest country market, anchored by Corning’s domestic tubing and Valor Glass manufacturing footprint and Chemglass Life Sciences’ dedicated laboratory glassware production. Canada is witnessing steady demand tied to its biotechnology and diagnostics sector, while Mexico’s growing pharmaceutical packaging and medical device manufacturing base is supporting incremental regional demand for converted borosilicate glass products.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, supported by expanding pharmaceutical production, solar thermal water heating installation, and electronics assembly capacity across China and India. China is the region’s largest country market, supported by domestic producers including Shandong Pharmaceutical Glass and HIMIN Solar, the latter a leading manufacturer of borosilicate evacuated tube solar collectors. India is witnessing the fastest country-level growth, driven by SCHOTT’s 2025 launch of local syringe and cartridge glass tubing production in Gujarat and continued capacity investment from domestic producers including Borosil Scientific and PGP Glass, while Japan maintains a mature, technologically advanced market anchored by Nippon Electric Glass and Nipro Corporation.

Countries and Regions Covered

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• Germany (Largest Country Market)
• France
• United Kingdom
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The Borosilicate Glass Market is consolidated, with a small group of large global tubing and vial manufacturers including SCHOTT, Corning, Nippon Electric Glass and Nipro controlling the majority of pharmaceutical-grade tubing production, alongside specialized converters including Gerresheimer, Stevanato Group and SGD Pharma that transform tubing into finished vials, ampoules and syringes. This two-tier structure, spanning upstream tubing manufacturers and downstream converters, means competitive intensity is shaped by vertical integration and quality certification as much as by production scale. Leading companies are prioritizing capacity expansion in emerging pharmaceutical markets, ready-to-use and pre-sterilized vial formats, and post-consumer recycled content certification, while regional producers in India and China are investing to reduce import dependence for domestic pharmaceutical and laboratory glass demand.

Key Players

• SCHOTT AG (Germany)
• Corning Incorporated (United States)
• Nippon Electric Glass Co., Ltd. (Japan)
• Nipro Corporation (Japan)
• DWK Life Sciences GmbH (Germany)
• Gerresheimer AG (Germany)
• Stevanato Group S.p.A. (Italy)
• SGD Pharma (France)
• Borosil Scientific Limited (India)
• PGP Glass (India)
• Shandong Pharmaceutical Glass Co., Ltd. (China)
• KAVALIERGLASS a.s. (Czech Republic)
• Chemglass Life Sciences (United States)
• Cangzhou Four Star Glass Co., Ltd. (China)
• Shandong HonHai Industrial Group Co., Ltd. (China)

Recent Market Developments

• In May 2026, Borosil Limited’s board approved manufacturing capacity investments including a new glassware production facility in Bharuch, Gujarat, and an expansion of its borosilicate glass furnace capacity for pressware products at its Jaipur, Rajasthan facility.
• In May 2025, Nipro PharmaPackaging expanded its Pune, India manufacturing facility to add high-precision Type I borosilicate glass cartridge production lines. The added capacity caters specifically to increasing Asian market demand for glass cartridges used in dental applications and pen-injector systems for targeted drug delivery.
• In October 2025, Gerresheimer AG broke ground on a €30 million expansion of its Wertheim facility in Germany. The new 4,000 m² production hall will serve as a European Center of Excellence for manufacturing high-durability Type I borosilicate glass injection vials (Gx Elite) and ready-to-fill (RTF/RTU) vials using its EZ-fill Smart packaging platform to support sensitive biologic therapies.
• In September 2025, Corning Incorporated and SGD Pharma inaugurated a new ?530-crore joint-venture pharmaceutical glass tubing manufacturing plant in Telangana, India. The facility co-locates Corning's Type I borosilicate glass tubing production with Velocity® Vial coating technology and SGD Pharma’s vial-converting expertise to expand regional primary packaging supply for injectable biopharmaceuticals and biologics.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is Borosilicate Glass?

2

What is the CAGR of the Borosilicate Glass Market?

3

Which type leads the Borosilicate Glass Market?

4

Which application dominates the Borosilicate Glass Market?

5

Which manufacturing process has the highest market share?

6

What are the latest trends in the Borosilicate Glass Market?

7

Who are the end users of Borosilicate Glass?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates